Diffuse large B-cell lymphoma is the most common type of non-Hodgkin’s lymphoma, accounting for about 30% of all non-Hodgkin’s lymphomas. Also, diffuse large B-cell lymphoma is a highly aggressive form of lymphoma that requires prompt treatment. In the past, the most common approach for diffuse large B-cell lymphoma was CHOP regimen chemotherapy, which included cyclophosphamide, vincristine, adriamycin, glucocorticoids, etc. In recent years, the prognosis of diffuse large B-cell lymphoma has been significantly improved by the application of the molecularly targeted drug melphalan, which is a molecularly targeted drug that specifically binds to CD20-positive lymphoma cells, acting as a precise strike against lymphoma cells and significantly improving the therapeutic effect. In addition. Patients with diffuse large B-cell lymphoma with poor prognosis can also be treated with autologous hematopoietic stem cell transplantation with good results.